top of page
  • Writer's pictureANPDF

Zevra Therapeutics Media Release | November 20, 2023

Zevra announces the completion of its acquisition of Acer Therapeutics. Zevra states they are committed to the arimoclomol expanded access program as a much-needed treatment of NPC, and their goal is to resubmit the arimoclomol New Drug Application (NDA) to the FDA by the end of 2023.


Read the full statement from Zevra Therapeutics here:

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a L
.
Download • 98KB

 

To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."


Ways to support NP-C in Australia:

42 views0 comments

Comentarios

Obtuvo 0 de 5 estrellas.
Aún no hay calificaciones

Agrega una calificación
bottom of page